BioMarck Pharmaceuticals Closes $6.3M Series C Financing Round

Strong commitment from existing shareholders provides financing to support completion of the ongoing Phase 2 clinical study of BIO-11006

Research Triangle Park, N.C (April 6, 2009)

BioMarck Pharmaceuticals, Ltd., a research company involved in the treatment of respiratory diseases announced today that it has closed its Series C round of financing for over $6.3 million – the majority of the financing that closed out the Series C round was made possible through the commitment of existing shareholders. The proceeds of this transaction together with the recently announced grant of $990,000 by the National Institute of Health will support the growth of the company through its ongoing phase 2 clinical study that will determine the safety and efficacy of BIO-11006 Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD).

Allen F. Gant, Chairman and CEO stated, “This is a powerful endorsement of our mission to treat COPD and other respiratory diseases associated with the over secretion of mucus and pulmonary inflammation. I am delighted to have closed the round in a period that has seen unprecedented financial turmoil Worldwide, and at a time when biotech funding is more arduous. BioMarck has generated significant value since our prior financing round and this is reflected in the strong support from our shareholders.”

About BioMarck Pharmaceuticals

BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. BioMarck licensed its technology on a worldwide exclusive basis from North Carolina State University. For more information on BioMarck, please visit its website at www.biomarck.com.

About BIO-11006 Inhalation Solution

BIO-11006 inhibits the function of the MARCKS protein (myristoylated alanine-rich C kinase substrate), which has been shown to be a vital component for secretion of mucus and inflammatory mediators. These two inhibitory aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models of airway disease.

About COPD

It is expected that more than 50 million individuals worldwide will suffer from COPD by 2010. In the United States alone, COPD affects at least 12 million patients and causes 120,000 deaths per year, making it the 4th leading cause of death. COPD is generally defined by a limitation of airflow in the lungs. This limited airflow may result from repetitive lung injury and inappropriate injury repair in lung. The airways of the lungs are normally covered by mucus that protects the airways from dehydration, pathogens, chemicals, inflammation, reactive oxygen species, and particulate irritants. However, in response to repetitive irritant exposure from cigarette smoke, for example, excessive secretion of mucus and inflammation occurs. Excessive secretion of mucus and inflammation are a common and distinguishing feature of COPD/chronic bronchitis, and studies conducted in the last several decades demonstrate the contribution of excessive mucus to the restriction of airflow in the lungs. However, there are no drugs that specifically inhibit excessive mucus secretion in the lungs; development of BIO-11006 Inhalation Solution may fill this therapeutic gap.

Company Contact:

Simon Fitall

sfitall@biomarck.com

www.biomarck.com

The content of this release is solely the responsibility of BioMarck. This press release might contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "could," "will," "would," "expect," "plan," "believe," "estimate," "predict," "plan," "intend," "goal," or the negative of such terms or other similar expressions. Forward-looking statements reflect our current expectations and views about future events as of the time we published these documents. The forward-looking statements involve known and unknown risks, uncertainties and other factors that might cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on any such forward-looking statements. In addition, the information in this press release is believed to be accurate as of the date hereof, but should not necessarily be relied upon to reflect management's current views at any future date.